EDE Dengue monoclonal antibodies
Clinical ready Human monoclonal antibodies targeting dengue’s conserved envelope dimer epitope, enabling cross-serotype neutralisation for passive protection and serotype-agnostic prophylaxis or treatment.
Home>Pharma/Biopharma
E-esmotrode – a concentric electrode electroosmotic pump
A flexible implantable electroosmotic pump enabling precise drug delivery through innovative concentric electrode design and laser-micromachined integration
Stacked thin-film electrode electroosmotic pump
A thin, wearable or implantable electroosmotic pump driving fluid through a high-density array of via holes, offering customisable, low-profile drug delivery and diagnostic sampling with laser fabrication
Synthetic immunogens for blood stage malaria vaccine against plasmodium falciparum
Researchers have engineered synthetic vaccine immunogens containing key epitopes that elicit potent growth-inhibitory antibodies against malaria targets RH5 and CyRPA, including PfRH5-34EM, PfRH5-top and PfCyRPA-BD.
Activators of PAK1 and PAK2 for the treatment of cardiovascular disease
PAK1 and PAK2 proteins that help heart cells (cardiomyocytes) maintain normal function and energy balance, enabling them to better adapt to stress.
Novel variants of cell penetrating peptides to improve therapeutic delivery
A new CPP design optimises Arginine placement to boost delivery efficiency and minimise toxicity, resulting in significantly improved therapeutic delivery performance.
RNA therapy for neurodegenerative, cardiac, and pulmonary disease
ASO therapeutic targeting MEG3 for neurodegenerative diseases, including Alzheimer's
Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for Plasmodium vivax
Successful development of readily producible and scalable new vaccine immunogens based on Duffy binding protein (PvDBP) of Plasmodium vivax
Stabilised class III viral fusion proteins for more effective immunisation of rabies disease
Class III fusion proteins, found on key viruses, can be stabilised in their pre-fusion form to preserve antibody-targeting sites, making them valuable for vaccine development.
Small-molecule degraders for Nudix Hydrolase 5, NUDT5
Novel degrader molecules that degrade rather than inhibit human NUDT5 for therapeutic benefit.
© Oxford University Innovation